Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors

Simple Summary Solid tumors account for ~60% of pediatric, as well as adolescent and young adult (AYA), cancers, and outcomes for patients with these progressive diseases remain poor. This highlights the critical need to develop tumor models from patients with aggressive cancers so that oncogenic signatures can be identified for therapeutic testing. Thus, patient-derived xenografts (PDXs) were established from sarcoma and Wilms tumor patients at diagnosis or following treatment. Overall, the molecular landscape of serially passaged PDXs recapitulated the original tumor based on an integrated multi-OMICS pipeline that cross-validated cancer-associated pathways. Actionable mechanisms of tumor progression were identified. CDK4/6 and BETs were prioritized as biomarkers of therapeutic response for in vivo validation. In osteosarcoma PDXs harboring pertinent molecular signatures, inhibition of CDK4/6 or BETs decreased growth. This systematic approach that links patient disease history to data generated from its corresponding PDX provides a foundation to discover improved therapies for patients with high-risk cancers. Abstract Establishment of clinically annotated, molecularly characterized, patient-derived xenografts (PDXs) from treatment-naïve and pretreated patients provides a platform to test precision genomics-guided therapies. An integrated multi-OMICS pipeline was developed to identify cancer-associated pathways and evaluate stability of molecular signatures in a panel of pediatric and AYA PDXs following serial passaging in mice. Original solid tumor samples and their corresponding PDXs were evaluated by whole-genome sequencing, RNA-seq, immunoblotting, pathway enrichment analyses, and the drug–gene interaction database to identify as well as cross-validate actionable targets in patients with sarcomas or Wilms tumors. While some divergence between original tumor and the respective PDX was evident, majority of alterations were not functionally impactful, and oncogenic pathway activation was maintained following serial passaging. CDK4/6 and BETs were prioritized as biomarkers of therapeutic response in osteosarcoma PDXs with pertinent molecular signatures. Inhibition of CDK4/6 or BETs decreased osteosarcoma PDX growth (two-way ANOVA, p < 0.05) confirming mechanistic involvement in growth. Linking patient treatment history with molecular and efficacy data in PDX will provide a strong rationale for targeted therapy and improve our understanding of which therapy is most beneficial in patients at diagnosis and in those already exposed to therapy.

[1]  K. Pollok,et al.  Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas , 2022, Cancers.

[2]  M. Sanchez-Martin,et al.  Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway , 2022, Cancer Research.

[3]  H. Asadzadeh Aghdaei,et al.  Patient-derived xenograft (PDX) models, applications and challenges in cancer research , 2022, Journal of translational medicine.

[4]  G. Piazza,et al.  The path to the clinic: a comprehensive review on direct KRASG12C inhibitors , 2022, Journal of experimental & clinical cancer research : CR.

[5]  E. Tufte The visual display of quantitative information , 1984, The SAGE Encyclopedia of Research Design.

[6]  E. Petricoin,et al.  Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  I. Vivanco,et al.  Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine , 2021, Pharmacogenomics and personalized medicine.

[8]  C. Hammer,et al.  Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non–Small-Cell Lung Cancer , 2021, JCO global oncology.

[9]  Benjamin J. Raphael,et al.  Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment , 2021, Nature Communications.

[10]  P. Ekert,et al.  Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[11]  R. Bindra,et al.  Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity , 2021, Translational oncology.

[12]  M. Barenboim,et al.  The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies , 2021, The Journal of pathology.

[13]  M. Georgescu,et al.  Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs , 2021, Acta neuropathologica communications.

[14]  Y. Asmann,et al.  Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups , 2021, npj Precision Oncology.

[15]  Luyi Wu,et al.  Cofilin: A Promising Protein Implicated in Cancer Metastasis and Apoptosis , 2021, Frontiers in Cell and Developmental Biology.

[16]  C. Steele,et al.  Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma , 2020, Nature Communications.

[17]  S. Burgos,et al.  Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways , 2020, Cancer Research.

[18]  S. Carr,et al.  Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML , 2020, JCI insight.

[19]  Hui-Zi Chen,et al.  Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance , 2020, British Journal of Cancer.

[20]  Ya Zhang,et al.  Targeting the Wnt/β-catenin signaling pathway in cancer , 2020, Journal of Hematology & Oncology.

[21]  Haocai Chang,et al.  Targeting autophagy to overcome drug resistance: further developments , 2020, Journal of Hematology & Oncology.

[22]  S. Abdelhak,et al.  Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size , 2020, Journal of Translational Medicine.

[23]  A. Jemal,et al.  Cancer statistics for adolescents and young adults, 2020 , 2020, CA: a cancer journal for clinicians.

[24]  G. Risbridger,et al.  PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery , 2020, Journal of the Endocrine Society.

[25]  S. Makin The RNA and protein landscape that could bring precision medicine to more people , 2020, Nature.

[26]  Lang Li,et al.  Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma , 2020, Cancers.

[27]  Brent S. Pedersen,et al.  Effective variant filtering and expected candidate variant yield in studies of rare human disease , 2020, npj Genomic Medicine.

[28]  S. J. Henley,et al.  Pediatric cancer mortality and survival in the United States, 2001‐2016 , 2020, Cancer.

[29]  J. Teer,et al.  TRIM28 congenital predisposition to Wilms’ tumor: novel mutations and presentation in a sibling pair , 2020, Cold Spring Harbor molecular case studies.

[30]  Dan J Stein,et al.  Genetic variants for head size share genes and pathways with cancer , 2020, bioRxiv.

[31]  Qianqian Lei,et al.  Identification of potential crucial genes and key pathways in osteosarcoma , 2020, Hereditas.

[32]  Xiaojing Wang,et al.  PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models , 2020, bioRxiv.

[33]  Rebecca M. Brock,et al.  Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for ex vivo Irreversible Electroporation Testing , 2020, Frontiers in Oncology.

[34]  J. Demongeot,et al.  Why Is AUG the Start Codon? , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  S. M. Asghari,et al.  Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer , 2020, Molecular Biology Reports.

[36]  A. Stathis,et al.  Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? , 2020, International journal of molecular sciences.

[37]  Xianqun Fan,et al.  The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance , 2020, International journal of cancer.

[38]  Anton G. Henssen,et al.  Current and Future Treatment Strategies for Rhabdomyosarcoma , 2019, Front. Oncol..

[39]  Nikos Koundouros,et al.  Reprogramming of fatty acid metabolism in cancer , 2019, British Journal of Cancer.

[40]  Steven B. Neuhauser,et al.  Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts , 2019, Nature Genetics.

[41]  A. Peraud,et al.  Compare and contrast: pediatric cancer versus adult malignancies , 2019, Cancer and Metastasis Reviews.

[42]  D. Calvisi,et al.  Axis inhibition protein 1 (Axin1) Deletion–Induced Hepatocarcinogenesis Requires Intact β‐Catenin but Not Notch Cascade in Mice , 2019, Hepatology.

[43]  T. Alonzo,et al.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group. , 2019, JCO precision oncology.

[44]  M. Ferracin,et al.  Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations , 2019, Scientific Reports.

[45]  S. J. Henley,et al.  Trends in pediatric cancer mortality and survival in the United States , 2019, Annals of Epidemiology.

[46]  Daniel Kuhn,et al.  Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies , 2019, Molecular and Cellular Biology / Genetics.

[47]  Stephen C. Grubb,et al.  Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines , 2019, BMC Medical Genomics.

[48]  Gregory P. Way,et al.  Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design , 2019, Cell reports.

[49]  S. Kong,et al.  Comparative analysis of whole-genome sequencing pipelines to minimize false negative findings , 2019, Scientific Reports.

[50]  P. Lange,et al.  Origins and clinical relevance of proteoforms in pediatric malignancies , 2019, Expert review of proteomics.

[51]  Lang Li,et al.  Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma , 2019, BMC Medical Genomics.

[52]  Yingchun Zhao,et al.  MicroRNA-539 inhibits the progression of Wilms’ Tumor through downregulation of JAG1 and Notch1/3 , 2018, Cancer biomarkers : section A of Disease markers.

[53]  Hejun Hu,et al.  Inhibition of protein kinase C activity inhibits osteosarcoma metastasis , 2018, Archives of medical science : AMS.

[54]  Pixu Liu,et al.  Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine , 2018, Oncology letters.

[55]  Gregory F Weber,et al.  TFEB-driven endocytosis coordinates MTORC1 signaling and autophagy , 2018, Autophagy.

[56]  Mari Masuda,et al.  Utility of Reverse-Phase Protein Array for Refining Precision Oncology. , 2019, Advances in experimental medicine and biology.

[57]  Hee-Jung Choi,et al.  Increased α2-6 sialylation of endometrial cells contributes to the development of endometriosis , 2018, Experimental & Molecular Medicine.

[58]  J. Yu,et al.  Hsp90ab1 stabilizes LRP5 to promote epithelial–mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression , 2018, Oncogene.

[59]  D. Adams,et al.  XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data , 2018, BMC Bioinformatics.

[60]  O. Slabý,et al.  Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis , 2018, International journal of molecular sciences.

[61]  R. Spurney,et al.  Regulation of cofilin phosphorylation in glomerular podocytes by testis specific kinase 1 (TESK1) , 2018, Scientific Reports.

[62]  Jing Sun,et al.  MUC16 mutations improve patients’ prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment , 2018, Oncoimmunology.

[63]  S. Batra,et al.  MUC16 as a novel target for cancer therapy , 2018, Expert opinion on therapeutic targets.

[64]  I. Barrett,et al.  The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models , 2018, Science Advances.

[65]  Chao Tu,et al.  Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas. , 2018, Oncology letters.

[66]  G. Mills,et al.  BRD4 facilitates replication stress-induced DNA damage response , 2018, Oncogene.

[67]  S. Agarwal,et al.  Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity , 2018, Scientific Reports.

[68]  J. Williams,et al.  Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field , 2018, Journal of clinical medicine.

[69]  Marissa Mattar,et al.  Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models , 2018, Front. Oncol..

[70]  Chang Xu,et al.  A review of somatic single nucleotide variant calling algorithms for next-generation sequencing data , 2018, Computational and structural biotechnology journal.

[71]  J. Buolamwini,et al.  Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy , 2018, Front. Pharmacol..

[72]  Hien Dang,et al.  The significance of intertumor and intratumor heterogeneity in liver cancer , 2018, Experimental & Molecular Medicine.

[73]  Jaeyun Jung,et al.  The Generation and Application of Patient-Derived Xenograft Model for Cancer Research , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[74]  Kshitij Srivastava,et al.  Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. , 2017, Cell metabolism.

[75]  Deena M A Gendoo,et al.  Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer , 2017, bioRxiv.

[76]  T. Weichhart,et al.  mTORC1 and mTORC2 as regulators of cell metabolism in immunity , 2017, FEBS letters.

[77]  M. Hidalgo,et al.  Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  D. Bexell,et al.  Patient-derived xenografts as preclinical neuroblastoma models , 2017, Cell and Tissue Research.

[79]  Anang A. Shelat,et al.  Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.

[80]  H. Rhim,et al.  Therapeutic implication of autophagy in neurodegenerative diseases , 2017, BMB reports.

[81]  M. Morelli,et al.  The cohesin complex prevents Myc-induced replication stress , 2017, Cell Death and Disease.

[82]  Fortunato Bianconi,et al.  Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study. , 2017, Oncotarget.

[83]  P. Chu,et al.  Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2− and ER+HER2+) breast cancers , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[84]  Ian C. McDowell,et al.  Transversions have larger regulatory effects than transitions , 2017, BMC Genomics.

[85]  C. Lang,et al.  FoxO1‐AMPK‐ULK1 Regulates Ethanol‐Induced Autophagy in Muscle by Enhanced ATG14 Association with the BECN1‐PIK3C3 Complex , 2017, Alcoholism, clinical and experimental research.

[86]  K. Yamaguchi,et al.  Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors , 2017, Scientific Reports.

[87]  W. Pao,et al.  Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors , 2017, Molecular oncology.

[88]  Haiyan Zhang,et al.  Activation of Wnt/β-catenin signalling via GSK3 inhibitors direct differentiation of human adipose stem cells into functional hepatocytes , 2017, Scientific Reports.

[89]  C. Rudin,et al.  Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis , 2016, PloS one.

[90]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[91]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[92]  C. Porta,et al.  Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[93]  Rafael Aldana,et al.  Sentieon DNA pipeline for variant detection - Software-only solution, over 20× faster than GATK 3.3 with identical results , 2016 .

[94]  E. Galanis,et al.  Aurora-A Kinase as a Promising Therapeutic Target in Cancer , 2016, Front. Oncol..

[95]  Karen Y. Oróstica,et al.  chromPlot: visualization of genomic data in chromosomal context , 2015, bioRxiv.

[96]  Tao Xie,et al.  Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression , 2015, PloS one.

[97]  A. Stoltzfus,et al.  On the Causes of Evolutionary Transition:Transversion Bias , 2015, bioRxiv.

[98]  Chi-Ping Day,et al.  Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.

[99]  P. Rutkowski,et al.  Trametinib: a MEK inhibitor for management of metastatic melanoma , 2015, OncoTargets and therapy.

[100]  Jesika S. Faridi,et al.  Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer. , 2015, Biochemical and biophysical research communications.

[101]  Charles J Malemud,et al.  The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? , 2015, Future medicinal chemistry.

[102]  H. Dombret,et al.  BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells , 2015, Oncotarget.

[103]  Karl-Friedrich Becker,et al.  Reverse Phase Protein Arrays—Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use , 2015, Microarrays.

[104]  Jayasha Shandilya,et al.  A role of WT1 in cell division and genomic stability , 2015, Cell cycle.

[105]  Kathy Pritchard-Jones,et al.  The yin and yang of kidney development and Wilms’ tumors , 2015, Genes & development.

[106]  J. Visvader,et al.  Patient-derived xenograft models of breast cancer and their predictive power , 2015, Breast Cancer Research.

[107]  Chris Sander,et al.  Spatial Normalization of Reverse Phase Protein Array Data , 2014, PloS one.

[108]  N. Ikegaki,et al.  Aurora kinase A is a possible target of OSU-03012 to destabilize MYC family proteins , 2014, Oncology reports.

[109]  P. Tighe,et al.  A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS) , 2014, European journal of immunology.

[110]  J. Gonzalez-Bosquet,et al.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress , 2014, Molecular Cancer.

[111]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[112]  C. Creighton,et al.  Erratum to: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and Histologic characteristics of human cancers , 2014, Journal of Translational Medicine.

[113]  L. Titus,et al.  Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival , 2014, PloS one.

[114]  V. Petrozza,et al.  Correlation of the Rac1/RhoA Pathway With Ezrin Expression in Osteosarcoma , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[115]  K. Pritchard-Jones,et al.  Wilms' tumor: biology, diagnosis and treatment. , 2014, Translational pediatrics.

[116]  C. Keller,et al.  Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma , 2014, PLoS genetics.

[117]  P. Colombo,et al.  Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse , 2013, Molecular oncology.

[118]  A. Marino Gammazza,et al.  Geldanamycin-Induced Osteosarcoma Cell Death Is Associated with Hyperacetylation and Loss of Mitochondrial Pool of Heat Shock Protein 60 (Hsp60) , 2013, PloS one.

[119]  Vivek Subbiah,et al.  Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing’s Sarcoma (EWS/FLI1) and Wilms’ Tumor(WT1) , 2013, PloS one.

[120]  Simen Myhre,et al.  Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins , 2013, Molecular oncology.

[121]  Yun-chi Tang,et al.  Gene Copy-Number Alterations: A Cost-Benefit Analysis , 2013, Cell.

[122]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[123]  P. Curatolo,et al.  Send Orders of Reprints at Reprints@benthamscience.org Mtor Inhibitors in Tuberous Sclerosis Complex , 2022 .

[124]  Yih-Leong Chang,et al.  KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells , 2012, PloS one.

[125]  F. Locatelli,et al.  Notch signaling in pediatric soft tissue sarcomas , 2012, BMC Medicine.

[126]  E. Petricoin,et al.  Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping , 2012, Clinical Cancer Research.

[127]  J. Squire,et al.  The Genetics of Osteosarcoma , 2012, Sarcoma.

[128]  Morag Park,et al.  Models of crk adaptor proteins in cancer. , 2012, Genes & cancer.

[129]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[130]  J. M. Davison,et al.  Wilms Tumor Gene on X Chromosome (WTX) Inhibits Degradation of NRF2 Protein through Competitive Binding to KEAP1 Protein* , 2012, The Journal of Biological Chemistry.

[131]  P. Ray,et al.  Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. , 2012, American journal of nuclear medicine and molecular imaging.

[132]  Yun-Xin Fu,et al.  Incorporating predicted functions of nonsynonymous variants into gene-based analysis of exome sequencing data: a comparative study , 2011, BMC proceedings.

[133]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[134]  C. Khanna,et al.  Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells. , 2011, Veterinary and comparative oncology.

[135]  Bing Wang,et al.  Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas , 2011, Journal of experimental & clinical cancer research : CR.

[136]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[137]  Chuan-Yun Li,et al.  KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases , 2011, Nucleic Acids Res..

[138]  P. Davies,et al.  Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and RSVA405, Inhibit Adipogenesis , 2011, Molecular medicine.

[139]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[140]  David M. Thomas,et al.  Cyclin E1 is amplified and overexpressed in osteosarcoma. , 2011, The Journal of molecular diagnostics : JMD.

[141]  V. Huff,et al.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene , 2011, Nature Reviews Cancer.

[142]  E. Petricoin,et al.  Reverse phase protein microarrays: fluorometric and colorimetric detection. , 2011, Methods in molecular biology.

[143]  Y. Shaul,et al.  c-Abl tyrosine kinase in the DNA damage response: cell death and more , 2011, Cell Death and Differentiation.

[144]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[145]  N. Jaffe,et al.  Pediatric and adolescent osteosarcoma , 2010 .

[146]  K. Guan,et al.  A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.

[147]  Matthew D. Young,et al.  Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.

[148]  Alan F. Rubin,et al.  Mutation patterns in cancer genomes , 2009, Proceedings of the National Academy of Sciences.

[149]  D. Hughes How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. , 2009, Cancer treatment and research.

[150]  W. Siess,et al.  Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. , 2009, Blood.

[151]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[152]  L. Ngoka Sample prep for proteomics of breast cancer : proteomics and gene ontology reveal dramatic differences in protein solubilization preferences of radioimmunoprecipitation assay and urea lysis buffers , 2008 .

[153]  M. Takimoto,et al.  Involvement of c-Abl and D40 (AF15Q14/CASC5) proteins in the regulation of cell proliferation and cancer , 2008, Cell and Tissue Biology.

[154]  M. Ladomery,et al.  New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes. , 2008, American journal of physiology. Renal physiology.

[155]  Mariaelena Pierobon,et al.  Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.

[156]  R. Levine,et al.  Myeloproliferative disorders. , 2008, Blood.

[157]  B. Burgering,et al.  Stressing the role of FoxO proteins in lifespan and disease , 2007, Nature Reviews Molecular Cell Biology.

[158]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[159]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[160]  S. Goff,et al.  Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. , 2004, Genes & development.

[161]  Yingnian Yu,et al.  ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. , 2003, Carcinogenesis.

[162]  V. Krymskaya Tumour suppressors hamartin and tuberin: intracellular signalling. , 2003, Cellular signalling.

[163]  P. Chène Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[164]  Francisca Vazquez,et al.  Phosphorylation of the PTEN Tail Regulates Protein Stability and Function , 2000, Molecular and Cellular Biology.

[165]  G. Nebl,et al.  Dephosphorylation of Serine 3 Regulates Nuclear Translocation of Cofilin* , 1996, The Journal of Biological Chemistry.

[166]  G. Basso,et al.  Analysis of cyclin‐dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma , 1996, Genes, chromosomes & cancer.